Lung Cancer Trials Ask AI to find trials
TerminatedPhase 1 / Phase 2NCT00807612
Official study title

QUILT-2.017: Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for 1st Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

Study summary

This is a global, multicenter, 2-part, open-label phase 1b and single-arm phase 2 study designed to evaluate the safety and efficacy of AMG 479 in combination with paclitaxel and carboplatin for the first-line treatment of advanced squamous non-small cell lung carcinoma.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedAMG 479 and AMG 479

Plus 3 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 25, 2024 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1 / Phase 2

Interventional

Where is it offered?25 U.S. locations

Locations may change over time.

Who runs it?NantCell, Inc.

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1 / Phase 2
Sponsor
NantCell, Inc.
Interventions being studied
Biological: AMG 479; Biological: AMG 479; Drug: Carboplatin; Biological: AMG 479; Drug: Paclitaxel
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Treatment approach
Chemotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Histologically or cytologically confirmed advanced squamous NSCLC
  • Measurable disease as defined per modified RECIST criteria
  • ECOG performance status of 0 or 1
  • ≥18 years old
  • Adequate glycemic function, for subjects with known diabetes
Reasons someone may not be able to joinExclusion criteria
  • Untreated or symptomatic central nervous system (CNS) metastases
  • Prior anti-cancer therapy as follows: Any prior chemotherapy for squamous NSCLC; Any prior adjuvant or neoadjuvant chemotherapy for squamous NSCLC; Any prior chemoradiation for squamous NSCLC; Central (chest) radiation therapy ≤ 28 days prior to enrollment, radiation therapy for peripheral lesions≤14 days prior to enrollment for squamous NSCLC

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Research SiteFayetteville, Arkansas
  • Research SiteFayetteville, Arkansas
  • Research SiteFort Wayne, Indiana
  • Research SiteFort Wayne, Indiana
  • Research SiteIndianapolis, Indiana
  • Research SiteIndianapolis, Indiana
  • Research SiteIndianapolis, Indiana
  • Research SiteLafayette, Indiana
  • Research SiteLafayette, Indiana
  • Research SiteNew Albany, Indiana
  • Research SiteNew Albany, Indiana
  • Research SitePaducah, Kentucky

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 25, 2024. Always confirm current availability with the study team.

View original record ↗